Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial J Rosenstock, DL Lorber, L Gnudi, CP Howard, DW Bilheimer, PC Chang, ... The lancet 375 (9733), 2244-2253, 2010 | 217 | 2010 |
In vivo load measurements on osseointegrated implants supporting fixed or removable prostheses: a comparative pilot study. T Jemt, L Carlsson, A Boss, L Jörnéus International Journal of Oral & Maxillofacial Implants 6 (4), 1991 | 209 | 1991 |
Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans V Lecoultre, L Egli, G Carrel, F Theytaz, R Kreis, P Schneiter, A Boss, ... Obesity 21 (4), 782-785, 2013 | 162 | 2013 |
Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin K Rave, E Potocka, AH Boss, M Marino, D Costello, R Chen Diabetes, Obesity and Metabolism 11 (7), 715-720, 2009 | 148 | 2009 |
Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial P Raskin, S Heller, M Honka, PC Chang, AH Boss, PC Richardson, ... Diabetes, Obesity and Metabolism 14 (2), 163-173, 2012 | 116 | 2012 |
Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin AH Boss, R Petrucci, D Lorber Journal of diabetes science and technology 6 (4), 773-779, 2012 | 114 | 2012 |
Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin P Richardson, RA Baughman, E Potocka, AH Boss, R Petrucci US Patent 8,119,593, 2012 | 99 | 2012 |
Superior control of blood glucose in diabetes treatment WW Cheatham, AH Boss US Patent 7,943,572, 2011 | 80 | 2011 |
Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content AH Boss, R Petrucci, C Howard, A Mann US Patent 8,258,095, 2012 | 78* | 2012 |
Technosphere® Insulin Technology PC Richardson, AH Boss Diabetes technology & therapeutics 9 (S1), S-65-S-72, 2007 | 76 | 2007 |
Method of reducing serum proinsulin levels in type 2 diabetics W Cheatham, A Boss, A Pfuetzner US Patent App. 11/032,278, 2005 | 75 | 2005 |
Randomized forced titration to different doses of Technosphere® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 … CJ Tack, V Christov, BE de Galan, KM Derwahl, G Klausmann, ... Journal of diabetes science and technology 2 (1), 47-57, 2008 | 74 | 2008 |
Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents J Rosenstock, R Bergenstal, RA DeFronzo, IB Hirsch, D Klonoff, AH Boss, ... Diabetes Care 31 (11), 2177-2182, 2008 | 70 | 2008 |
Method of preserving the function of insulin-producing cells AH Boss, WW Cheatham, DC Diamond | 69 | 2007 |
Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA L Blonde, L Meneghini, XV Peng, A Boss, K Rhee, A Shaunik, S Kumar, ... Diabetes Therapy 9, 1347-1358, 2018 | 65 | 2018 |
Anchoring member L Jorneus, A Boss US Patent 5,269,685, 1993 | 65 | 1993 |
Methods and compositions for minimizing accrual of inhalable insulin in the lungs C Gelber, A Boss | 63 | 2006 |
Inhaled Technosphere®/Insulin: Glucose elimination at the right time? AH Boss, K Rave, WW Cheatham, T Heise Diabetes 54, A109, 2005 | 63 | 2005 |
Inhaled Technosphere® insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes K Rave, T Heise, L Heinemann, AH Boss Journal of Diabetes Science and Technology 2 (2), 205-212, 2008 | 62 | 2008 |
Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus H Zisser, L Jovanovic, K Markova, R Petrucci, A Boss, P Richardson, ... Diabetes Technology & Therapeutics 14 (11), 997-1001, 2012 | 61 | 2012 |